Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab

Marilynn Larkin  |  December 8, 2016

NEW YORK (Reuters Health)—Compared with cyclophosphamide, rituximab treatment poses less malignancy risk in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), European researchers report. Dr. Emma E. van Daalen of Leiden University Medical Center in the Netherlands tells Reuters Health, “Previous studies reported an increased malignancy risk in patients with AAV, which has been associated…

New Insights into the Structure of Collagen Fibril

Lara C. Pullen, PhD  |  December 5, 2016

A study of knee and hip articular cartilage found that thick fibers were bundles of thin fibrils—like a multi-thread rope in which each thread corresponds to a prototypic sub-fibril. The organization of the fibers also differed between the cartilages of distinct tissues, which may explain how a breakdown in the fiber pattern contributes to pathology…

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Effect of Diet & Sodium Intake on Serum Uric Acid

Arthritis & Rheumatology  |  November 29, 2016

Serum uric acid (UA) is an important factor in the causal pathway for gout. It has also been implicated as a potential risk factor and/or mediator of cardiovascular disease outcomes and mortality in a large number of observational studies. Although many of the clinical trials targeting serum UA reduction have focused on pharmacologic interventions, diet…

Shingles Vaccination Not at Goal Levels for U.S. Seniors

Madeline Kennedy  |  November 28, 2016

(Reuters Health)—Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster (shingles), despite recommendations that all of them should get the shot. It’s estimated that among people over age 50, one in three will eventually develop shingles. After age 80, half of adults have…

Varicella Zoster Virus Downregulates Programmed Death & Promotes Inflammation

Lara C. Pullen, PhD  |  November 28, 2016

A recent study found that the varicella zoster virus downregulates expression of programmed death ligand 1 and major histocompatibility complex 1 in brain fibroblasts, perineurial cells and lung fibroblasts. These effects may lead to persistent inflammation in the vessels and lungs, as well as promote subsequent infection of T cells and the spread of the virus…

Patients with Parkinson’s Disease Are at Risk for Carpal Tunnel Syndrome

Lara C. Pullen, PhD  |  November 21, 2016

Patients with Parkinson’s disease may be at risk of carpal tunnel syndrome (CTS). New research examined why patients with Parkinson’s have a higher incidence of CTS than that of the general population. The study found that those patients who underwent subthalamic nucleus deep brain stimulation to monitor them for neuropathy may develop CTS…

Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy

Megan Brooks  |  November 18, 2016

NEW YORK (Reuters Health)—Patients with active rheumatoid arthritis (RA) and no known heart disease may have subclinical myocardial inflammation, which improves with disease-modifying therapy, new research shows. “We know that patients with RA have higher risk of cardiovascular events, including heart failure and we really don’t know why. Maybe myocardial inflammation is one of the…

Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

Vanessa Caceres  |  November 16, 2016

A large medical specialty society for ophthalmologists recently updated its recommendations for the screening of chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy.1 The recommendations from the American Academy of Ophthalmology (AAO) affect patients who may use CQ or HCQ for rheumatoid arthritis or systemic lupus erythematosus (SLE), as well as some inflammatory and dermatologic conditions. The…

2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications

Mary Beth Nierengarten  |  November 16, 2016

In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2…

  • « Previous Page
  • 1
  • …
  • 204
  • 205
  • 206
  • 207
  • 208
  • …
  • 339
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences